Delivering the Promise of Healthier Lives®

OTCQB: CURR

one or more of these risks or uncertainties materialize, or should the underlying those from significantly differ may results actual incorrect, prove assumptions planned. or intended expected, estimated, believed, anticipated, Although the company believes that the expectations reflected in the forward future guarantee cannot company the reasonable, are statements looking results, levels performance of activity, achievements.or asExcept required by company the States, United the of laws securities the including law, applicable forward the of any update to intend not does these statements to actual results. information currently available to, the company’s management as well as used When management. company’s the by made and assumptions estimates in this presentation the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions forward identify management company’s the or company the to relate as they statements. looking Such statements reflect the current view of the company with respect to and other assumptions uncertainties, risks, to subject and are events future of and results operations its industry, company’s the to relating factors operations and any businesses that may be acquired by the company. Should To the extent any statements made in this presentation contains forward forward contains presentation made in this statements any extent the To and of, beliefs upon based are that and information statements looking

Statements Forward Looking Forward Our mission is to improve lives by redefining how medications are delivered and experienced. © 2020 CURE Pharmaceutical How we do it do we How We work companies with to shared with values market distribute and and products pharmaceutical supplements. dietary What we dowe What We improve absorption and and medicines of release supplements into the body for easier, safer and more effective administration.

™

CURE Pharmaceutical CUREform dosage forms: innovative formulations and develops and manufactures

delivery company that We are an advanced drug drug an advanced are We The Problem: Oral delivery is flawed

POOR BIOAVAILABILITY For many molecules given orally, only a fraction of the administered dose will make it to the blood due to poor solubility or degradation in the GI tract and liver.

SIDE EFFECTS When only a fraction of the administered dose reaches the blood, more drug needs to be given which can cause GI Almost 70% of Americans irritation and liver toxicities. are on prescription 1 medication. NON-ADHERENCE When drugs don’t work well enough and cause side effects, patients Oral drug delivery is the stop taking them. most preferred route of ● 30-50% of Americans do not take medications as prescribed.2 drug administration. ● 40% of patients have trouble swallowing pills.3

© 2020 CURE Pharmaceutical © 2020 CURE Pharmaceutical ™ CUREpods chewable pod technology ™ emulsions *magnification: 250x *magnification: CUREdrops CUREform™ ® Advanced drug formulation and delivery platform

CUREfilm

dissolving film technology film dissolving The Solution: © 2020 CURE Pharmaceutical pass pass - Multiple actives up actives to 200mg Multiple room at temperature Stable No need for water, swallowing or chewing or swallowing water, for Noneed Uniform drug distribution allows for precision dosing absorption into the bloodstream, avoiding first avoiding bloodstream, the into absorption metabolism Sublingual and buccal delivery options for direct for direct options delivery buccal and Sublingual Suitable for both pharmaceuticals and nutraceuticals and pharmaceuticals for both Suitable

● ● ● ● ● ● Applications Dose LoadingDose Unique Attributes Dissolving film technology filmDissolving The Right Form Dosage CUREfilm® © 2020 CURE Pharmaceutical magnification: 250x magnification: ™ Stable at room at temperature Stable Multiple actives up actives to 100mg/ml ofMultiple emulsion creams, etc.) Versatile encapsulation that can be incorporated incorporated be can that encapsulation Versatile tincture, film, (thin forms dosage different into bioavailability and stability of hydrophobic or hydrophobic of stability and bioavailability lipophilic molecules Proprietary encapsulation techniques to increase Suitable for both pharmaceuticals and nutraceuticals and pharmaceuticals for both Suitable

● ● ● ● ● Applications Dose LoadingDose Unique Attributes Proprietaryemulsion technology The Right Form Dosage CUREdrops © 2020 CURE Pharmaceutical problems with poorly soluble and poorly and poorly soluble with problems High doses of actives (grams) actives of doses High Ideal for sports wellness absorbed nutrients nutrients absorbed flavors sizes, and colorsshapes, Multiple Simultaneously load fat soluble and water soluble molecules soluble water and soluble load fat Simultaneously Overcomes

● ● ● ● ● Applications Dose LoadingDose Unique Attributes Chewable pod technology pod Chewable The Right Form Dosage CUREpods™ CUREinside Quality

Starting in February 2020, our partners' products will bear our symbol of quality, Powered By CURE™

This quality mark highlights our commitment to high- quality products produced under strict governmental and internal quality standards.

© 2020 CURE Pharmaceutical © 2020 CURE Pharmaceutical ease of use EXPERIENCE BETTER PATIENT PATIENT BETTER Effective symptom symptom Effective masking, and overall relief, improved taste taste improved relief, SPECIFIC (e.g. immediate or immediate (e.g. controlled release) RELEASE PROFILES RELEASE PROTECTION and throughout shelf throughout and during manufacturing, manufacturing, during FROM DEGRADATION retention in retention target tissue INCREASED

permeability and and permeability

BIOAVAILABILITY BIOAVAILABILITY solubility, enhanced through greater water

The Right Formulation CUREform™ Strategic Approach

NUTRACEUTICALS CANNABINOIDS

Target the growing CUREfilm® + CUREdrops™ wellness market cannabinoid formulations as nutraceuticals and No FDA approval required pharmaceuticals

Faster and cheaper encapsulation to stabilize to launch than and improve the pharmaceutical medicines bioavailability of

® cannabinoids and terpenes CUREfilm + CUREpods™ in oral, topical and transdermal dosage forms

PHARMACEUTICALS DEA Schedule 1 manufacturing license to CUREfilm® + CUREdrops™ formulate and improved drug formulations manufacture cannabinoid for accelerated approvals via drugs in-house 505(b)(2) regulations with market exclusivity © 2020 CURE Pharmaceutical © 2020 CURE Pharmaceutical patents pending patents 13+ patents U.S. issued 21 INTELLECTUAL PROPERTY FACILITY cGMP MANUFACTURING MANUFACTURING cGMP registered and audited facility - cGMP 25,000cGMP plant in sq production ft Oxnard, CA FDA Clean room environment and supplements dietary Pharmaceuticals, substancescontrolled schedule (DEA 1 manufacturing license) Expansion capability Custom drug delivery systems developed in a design control process ● ● ● ● ● ●

Capabilities AND SCALE UP SCALE AND PROCESS DEVELOPMENT CHARACTERIZATION PRODUCT ANDDEVELOPMENT Our Our © 2020 CURE Pharmaceutical • Royalties • Upfront fees • Upfront • Manufacturing fees • Manufacturing • Milestone payments • Milestone IN HOUSE PRODUCT & IN HOUSE CLINICAL DEVELOPMENT DEVELOPMENT CLINICAL • Royalties • License fees fees • License TECH TRANSFER TECH IP LICENSING AND IP LICENSING • Tech transfer fees transfer • Tech • Milestone payments • Milestone Streams

• Development fees • Development

• Manufacturing fees • Manufacturing AND MANUFACTURING MANUFACTURING AND CONTRACT DEVELOPMENT DEVELOPMENT CONTRACT Revenue Revenue © 2020 CURE Pharmaceutical Launch Launch Filing Regulatory ScaleUp Manufacturing Manufacturing Clinical Clinical Development Formulation Formulation Formulation Formulation Development Development IND) - (two different sleep & recovery products) recovery & sleep different (two (Sildenafil Pre (Sildenafil Caryophyllene Caryophyllene Caryophyllene (weekly vitamin D3)D3) vitamin vitamin (weekly (weekly -- Pipeline Sleep Sleep BLUE Canna (THC & CBD) & (THC Canna ®

CUREfilm® CUREfilm CUREfilm® DD CUREfilm® CUREfilm® ββ CUREfilm® CUREfilm® CUREfilm® Hemp Hemp CUREfilm® CUREfilm® CUREfilm® Pharmaceutical Wellness Product © 2020 CURE Pharmaceutical 5 6 4 7 8 9 2024. - 2025. 2022. 2025 2024. - - - - Global CAGR 2017 Global sales of Vitamin D supplements by 2025. Global CAGR 2019 Global sales of curcumin supplements by 2024. Global CAGR 2018 Global sales of erectile dysfunction drugs by 2024. Global CAGR by 2018 Global sales medical cannabis by 2025. Global CAGR 2019 Global sales of melatonin supplements by 2024. Global CAGR by 2023. Global sales of cannabidiol (CBD) by 2022. CAGR CAGR CAGR CAGR CAGR CAGR 31% 31% 7% 12.3% 5.7% 24.4% 19.9% 19.9% 7.1B $1.3B $ $20.2B $2.1B $1.9B $1.7B Caryophyllene - Hemp Hemp β Canna Blue D Sleep ® ® ® ® ® ® Opportunity

CUREfilm CUREfilm CUREfilm CUREfilm CUREfilm CUREfilm Market © 2020 CURE Pharmaceutical .. Business Business Jonathan Berlent Chief Officer FormerlycannabisCOOof SaaS technology pharmacy telehealth of CEO company, testing at Director Managing company, marketplace and N.A. of President consultancy, sciences life Operationsleading initiatives commercial for pharmaceuticals. branded and specialty generic, the from Economics in degree Bachelor’s in Master’s aand Michigan of University York New the from Administration Business Business of School Stern University ● ● Mike Redard Chief Financial Officer Technologies. Abrisa , Medical, Analysis Systems (acquired FormerlyvicepresidentCFO, and general and venture several with positions manager including companies backed equity private Inogen Advanced CDTi Scientific), Fisher Thermo by Materials,and Earlierexperience includes management withroles Pepsiand inpublic accounting. CPA(inactive) with a B.S., Business AdministrationCaliforniafrom Polytechnic StateUniversity, San Luis Obispo. ● ● ● Inc., ™, ™, ™, InnoZen Robert Davidson Chief Executive Officer Pediastrip Chloraseptic

Management,Master’s in Public Health, Mastersin Wellness, Post Graduate QualificationatCambridge.the University of B.S. degree in Biological Life Sciences; Sciences; Life Biological in degree B.S. MastersCertificate in Applied Project delivery technologies and commercial brand brand commercial and technologies delivery extensionsincluding Suppress™,as well as CEOof Gel Tech LLC, CEO of Bio Delivery TechnologiesInc. Leadthedevelopment several drug of FormerlyPresident and ofCEO

Our Executive Team: Executive Our ●

● ● © 2020 CURE Pharmaceutical Steven Ruhl Vice President, Manufacturing Over 35 years of experience leading experience of years 35 Over teams. technical Leadershipinprocessrolesdevelopment at AmgenThousand Oaks and Ireland Managementpositions at CancerVax, CertifiedFacilities, IDEC Pharmaceuticals, Pharmaceuticals. andCeltrix Xoma Trainedas microbiologist and chemist at University. Young Brigham ● ● ● ● Mark Udell Mark Chief Accounting Officer FormerlyChief Accounting Officer and Controllerat InnoZen, Inc. AuditingManager at HassonGreen & Angeles. Los in LLP Janks, CPAand B.A. in Business Economics accounting in concentration a with California, the University of from SantaBarbara. ● ● Medical - Vered Gigi Vered Chief Scientific Officer merger integration integration merger - Aviv University Aviv in -

Israel. PhDImmunologytheinUniversity from ofPennsylvania; BSc. in Bio Tel from sciences and network strategy, operations, operations, strategy, network and post and marketing initiatives. FormerProject Leader with the Boston ConsultingGroup focused on corporate FormerVP, Strategy and Business Pharmaceutical CURE with Development ● ● ● Our Executive Team: Team: Executive Our © 2020 CURE Pharmaceutical Graduate Qualification, University of Cambridge. - LLC, CEO of Biodelivery Technologies andBiodelivery Inc., of of Director CEO LLC, HealthSportInc. expertresponsibletheseveraldrugODF development of for extensions. brand commercial and technologies delivery Hasworkedwith brands such as Chloraseptic™, Suppress™, as film. thin oral electrolyte label private a Pediastrip™, as well New of State the of University Sciences, Life Biological B.S., College. Excelsior York, Master’sCertificate, Applied Project Management ,Villanova University Master’s,Public Health from American Military University, Virginia Mastersin Health and Wellness from Liberty University, Virginia CertifiedPerformance Enhancement Specialist and Fitness NutritionSpecialist, National SportsMedicine Academyof Post CEOof CURE Pharmaceutical FormerPresident and InnoZenof CEO Inc., GelTechofCEO ● ● ● ● ● ● ● ● Rob Davidson Rob ● ● based based - Directors

Kennedy School. Kennedy Technology,Media and Telecom. University Cornell from Economics in B.S. Attendedas aMason Fellowat Harvard University’s John F. Managedone ofthe largest pension /retirement funds in the portfolio. billion $488 a with world, Memberofthe International Who’s Who Finance,of Guided leading Asian institutions like Sina.com, Shanghai Petrochemicals,Jinlia Pharmaceutical and Tsingtao Corp. Beer LynchAssetMerrill Led Management Asia, Key strategist Key internationalandto advisor institutions. U.S. companiesinclude Amgen Corp., Biogen, Capital, GE Warner News. Fox and Studios, Brothers investmentbanking firm. years23 in global finance experience. Chairmanand CEO of Fortress Hill Holdings, an Asian ● ● ●

● ● ● ● ●

William Yuan (Chairman of the Board) the of (Chairman Yuan William Board of Board © 2020 CURE Pharmaceutical Collegeof - reviewed scientificjournals reviewed and - , Ph.D. Chung founder of TokumCapital,founder globalof a healthcare fund (merged - operational,and commercial planning. years20 of healthcare investment management and advisory experience. FormerManaging Director in Healthcare Research at WestPark Capital. Co Partners.) Weinberg Perella with Managedhealthcare investment portfolios at RBR Capital, KingdonCapital,andCapital. Pequot recognizedA research scientist conducting cutting edge research Massachusetts at disorders genetic and neurodegenerative General Hospital/Harvard Medical School and Boston Children’s Hospital. Publishedmany leading peer companies. healthcare various in member board a as serves PhDNeuropathologyinColumbia University from PhysiciansSurgeons,& and withBAa honors Biochemistryin and Economicsfrom Wellesley College. FoundedLLC. identifying,MINLEIGH evaluating and partnering strategic, various and investments for companies with ● ● ● ● ● ● ● Lauren ● V) V) - Tech,Inc., a leader in the mobile - Directors

Crohn’sand Colitis Canada and the Stratford festival. numerous organizations including Cambridge Memorial Hospital, Hospital, Memorial Cambridge including organizations numerous and Council, Prosperity Region Waterloo Police, Regional Waterloo FormerandCEO director AutomationATS of and(TSX) its global 24 facilities. manufacturing philanthropistA who has contributed andto provided leadership for manufacturer of auto parts. auto of manufacturer Servedas chairman and principal shareholder of fleet management companyTechnologiesBSM Inc. (TSX Was the founder and CEO of Shred of CEO and founder the Was industry. shredding global a Inc., Technologies Polymer of CEO and owner the Was investmentfirm based inCambridge, Canada. Memberofa number ofpublic boards, most recently with DelMar Pharmaceuticals,which newdevelopstreatments cancer. for Servedas chairman of the Canopy Rivers board of directors Formerchairman theof board directorsof at Canopy Growth. Managingpartner at Onbelay Capital Inc., a private equity and

● ●

● ● ● ● ● John K. John Bell, ICD.D FCPA, FCA,

(continued) Board of Board © 2020 CURE Pharmaceutical State - worth worth - net - cannabisoperator licensed States.in 20 Founderand ChemistryofCEO Holdings, Inc. a formulation delivery sustainable innovative, creates that company technology was Holdings Chemistry industries. of variety a for systems recentlyacquiredPharmaceutical. Cure by CEOand founder of Made by Science (rebranded as Form Factory Inc). a private company acquired by Acreage Holdings for $160 Millionin December of2018. FormerVicePresident Investmentsof forJP Morgan, managing high for dollars investment in million than$100 more individualsand families. Beach. Long University, State California the from Arts of Bachelor Currentlythe President of Form Factory Inc. a wholly owned multi largest the (ARCG.CN) Holdings Acreage of subsidiary ● ● ● ● Joshua Held Joshua ● - up. up. - billion London Stock Exchange Stock London billion - Directors foundedLaboratories,technologyaProvenance start

JD from University of California Berkeley School of Law of School Berkeley California of University from JD A membertheA of State BarCalifornia of Berkeley California of University from Communications Mass in BA Capital. TrusteesWestmarkOnthe Boardand of of the onBoard School, of Alumni Law Berkeley of Chapter LA the private companies in Europe, Russia, India and the UK the and India Russia, Europe, in companies private theChair of BoardVice Directors a globalof for private equity fund equityprivatefund,Californiaa Boardof LumiaOn the Advisory Servedas the General Counsel, Vice President and Chair of the Risk ManagementCommittee ofa $20 and public eight of boards the on served and conglomerate listed A practicingA attorney at Nolan Heimann law firm Co years17 in leadership as a managing partner at Latham & Watkins 28 years28 of experience in law, private equity, venture capital, industries. telecommunications and healthcare Formerinternational business consultant ● ● ● ● ● ● ● ● ● ● ● ● Anya Goldin Anya

(continued) Board of Board © 2020 CURE Pharmaceutical invasive - and postgraduate training at Abington Memorial hospital, The The hospital, Memorial Abington at training postgraduate and Graduate Hospital, Veterans Administration Hospital, Pennsylvania Hospital,Children’s Hospital Philadelphia, of and theHospital the of Pennsylvania. of University MDfrom Temple University School ofMedicine and his Bachelor of Artsthefrom University Pennsylvania. of Numerousfaculty, hospital and administrative appointments at virtuallyeverymajor hospital in the northeastern Philadelphia and areas. surrounding pharmaceutical Prolific investorincluding IntuitiveSurgical, Pharmacyclics,whichless grewsharefrom than per to $1 and $250/share, for Abbvie by acquired being subsequently Centocor,acquired by Johnson & Johnson for $4.9 billion in stock. Sitson the board of DermTech, a private company based in San non in leader global the thathasbecome Diego diagnostics. molecular dermatological Board certified in neurological surgery by the American Board of of Board American the by surgery neurological in certified Board NeurologicalSurgeryand completedvarious residencies, fellowships ● ● ● ● Gene Salkind, MD ● Shaw Jr. - Directors

suite positions with leading private companies including Steward Steward including companies private leading with positions suite -

Business, Florida International University. Advanced studies in in studies Advanced University. International Florida Business, CorporateGovernance at the Harvard Business School. B.S., Industrial and Labor Relations, Cornell University, Master of of Master University, Cornell Relations, Labor and Industrial B.S., Administration HealthService and InternationalaMaster of Advisor,healthcare thetopolicy Trump Administration. Senioradvisor to the Secretary of the U.S. Treasury, health care tax policies. and Oversight Committee, Oversight and COOand deputy administrator of the Centers for Medicare and MedicaidServices, George W. Bush administration. Living Systems, of Miami, FL; andLivingFL; Systems,Miami,WellCare Health of Plans, of Inc. Tampa,FL. Servedon the Obama Administration's Medicare Program Advisory FormerBoard member, Cotiviti Holdings, Inc. and current Board FL. Pensacola, of Systems Imaging Retinal Intelligent member, FormerLead Director theof Board at Athenahealth; Independent C NeighborhoodHealth System,HealthLLC, Care Partnership, andInc. Plan. Health JMH ● ● ● ● ● ● ● ● Ruben Jose King RubenJose

(continued) Board of Board © 2020 CURE Pharmaceutical specializing in both commercial and residential properties. properties. residential and commercial both in specializing FounderWillnerof Capital, Inc., a basedFL investment concern traded publicly several with role activist an played has that companies. Investorin biotech, technology and security companies, with recentfocusincannabis related pharmaceutical companies Servedon the Board of Directors of publicly traded Meridian of Directors of Board the of Chairman Vice as served Bank, Intervoice,Inc. Heldpositions andat Milbank,Arthur HadleyMcCloy & Tweed, AndersenCompany& CPA and School Law University Emory from degree Doctor Juris FounderWillnerof Properties Services, Inc., a PAbased real estatedevelopment, leasing and management company ● ● ● ● ● Michael Willner, Esq. Willner, Michael ● infectiveDrug Advisory Committee and board certified -

inpediatrics, pediatric infectious diseases and atheFellow of AmericanClinicalCollege of Pharmacology. individualpatients. Memberofthe United States Food and Drug Administration Anti pharmacometrics, including population pharmacokinetic and pharmacokinetic population including pharmacometrics, simulation, pharmacogenomics, modeling, pharmacodynamic for therapy optimize to models of use importantly, most and HospitalAngeles.Los Researchand clinical interests areinpediatric clinical patients for over 35 years. 35 over for patients AssociateProfessorPediatrics, of Clinical Scholar at the Children’s atand (USC) California Southern of University ofApplied Pharmacokinetics, which has been at the nonparametric of populationforefront pharmacokinetic individual for optimization dose and techniques modeling Director of the University of Southern California Laboratory Laboratory California Southern of University the of Director ● ● ● Michael Neely, MD Neely, Michael ● Advisors © 2020 CURE Pharmaceutical -

Documents beto drafted by counsel theto company. Read those documents before making an investment decision. The securities are being offered in reliance upon in states the in 1993 and only of Act Securities the under registration from exemptions which the offering of securities is registered or is exempt from registration and by broker so. do to dealers authorized Pharmaceutical, or (2) a promise or representation that any such offer will be made to the the to be made will such offer any that representation or (2) a promise or Pharmaceutical, recipient any or other party. shall The offering be qualified investors. made to is made only being The offering and pursuantdocuments reasonably the the acceptableCompany Investors, to which to and representations basic form, (i) short things, other among shall contain, agreements warranties by the Company, and (ii) covenants of the Company reflecting the provisions closing. of conditions appropriate and herein forth set This Investor Presentation is supplied for informational purposes only and does not andnot does only purposes informational is supplied for Presentation This Investor (1) anbuy, of any securities anCURE sell,constitute of offer to offer to the solicitation or

Disclaimer Company © 2020 CURE Pharmaceutical (2018, (2018, (2018, Oct) (2018, 2025 - (2013) Mayo (2013) Clinic , (2018, July) Retrieved (2018, , (2013 May JAMA;(2013 22) 2022) - (2019, June) Retrieved from: from: Retrieved June) (2019, CurrentTherapeutic Research, (2018, Aug 2) Retrieved from: from: Retrieved Aug2) (2018, https://www.marketsandmarkets.com https://www.ncbi.nlm.nih.gov https://www.mayoclinicproceedings.org Size, Trends and Forecast 2018 Forecast and Size, Trends - (2019, May) Retrieved from: from: Retrieved May) (2019, 707 Retrieved from: from: Retrieved 707 - 82. doi:10.1016/j.curtheres.2015.08.002. Retrieved from: from: Retrieved doi:10.1016/j.curtheres.2015.08.002. 82. – Vitamin D Market by Analog (Vitamin D2, Vitamin D3), Form (Dry, Liquid), Application Application D3), Form (Dry, Liquid), D2, Vitamin Analog (Vitamin Dby Market Vitamin 2023 Global Melatonin Consumption Market Report Market Consumption Global Melatonin 2023 - Global Erectile Dysfunction Drugs Market Will Reach USD 7.10 Billion by 2024 2024 by USD Reach Billion Will 7.10 Drugs Market Dysfunction Global Erectile Global Medical Cannabis Market Insights, Forecast to 2025, to 2025, Forecast Insights, Market Cannabis Global Medical Pill Properties that Cause Dysphagia and Treatment Failure. Treatment and Dysphagia Cause that Properties Pill Curcumin Market Size, Share & Trends Analysis Report By Application (Pharmaceutical, Food, (Pharmaceutical, Application By Report Analysis & Size, Share Trends Market Curcumin Age and Sex Patterns of Drug Prescribing in a Defined American Population American a Defined in of Drug Prescribing Sex Patterns and Age Global CBD Oil Market Analysis Global CBDAnalysis Oil Market Global Forecast to 2025, to 2025, Global Forecast https://www.grandviewresearch.com , - 2018 copyright© Paul Bradbury, iStock Medication Nonadherence: A Diagnosable and Treatable Medical Condition Medical Treatable Diagnosable A and Nonadherence: Medication

https://www.globenewswire.com 2106. doi: 10.1001/jama.2013.4638 Retrieved from: from: Retrieved 10.1001/jama.2013.4638 doi: 2106. –

https://www.businesswire.com MarketsandMarketsInc., Women), Iu Pregnant and Adult, (Children, User Care), End Personal and Feed, FoodPharma, & Beverage, (Functional Region and Strength Grandview Research, 2018 Forecasts Segment MEA), And CSA, Europe, America, North Region Pacific, (Asia By Cosmetics), Sep)Retrieved from: TechnavioResearch from: MarketStudy Report, https://www.marketstudyreport.com Zhong,Wenjun etal. 697 Issue 7, Proceedings, Volume88, Marcum,Z. et al, 2105 309(20): Fields,J. et al. (2015). Clinicaland Experimental, 77, 79 https://www.ncbi.nlm.nih.gov IndustryResearch, https://www.industryresearch.co MarketZion Research, Retrievedfrom: 6. 7. 8. 9. 1. 2. 3. 4. 5. Title page photograph: page photograph: Title References: Credits